



Collaborative Working Executive Summary

Project title	West of Scotland Cancer Network (WoSCAN) Non Melanoma Skin Cancer Pathway Analysis & Improvement Project
Partner organisation/s	West of Scotland Cancer Network Sanofi
Project rationale	<p>Analyse and define the current patient pathways and processes for NMSC patients (CSCC and BCC) across the West of Scotland Cancer Network.</p> <p>Identify sections of the pathway where potential process improvements could be made which if implemented would lead to a reduction of identified variations in service delivery and to optimal standardised practice.</p> <p>Develop a list of options allowing the WoSCAN Skin Cancer Managed Clinical Network to target potential areas for pathway improvement and/or transformation.</p> <p>It has been agreed that the work undertaken will take place in NHSGGC as this is where the main Cancer Centre is located in the WoSCAN geographical area.</p>
Project period	Q1 2022- Q2 2022
Project objectives	<p>Potential benefits for Patients</p> <ul style="list-style-type: none"> • Improved equity of pathway access, provision, and experience for patients with suspicious skin lesions in particular BCC and CSCC, ensuring that patients receive appropriate care, in the right place and in a timely manner. • To support the timely diagnosis of Non Melanoma Skin Cancer and provide personalised, risk stratified support & education. <p>Potential benefits to the NHS</p> <ul style="list-style-type: none"> • Improved and more efficient patient pathways for BCC and SCC across WoSCAN & NHS Greater Glasgow & Clyde. • Improved identification of patients • More appropriate referrals into the pathway/service.



	<ul style="list-style-type: none">• Reductions in unwarranted variations in care and an increase in patients appropriately diagnosed with skin cancer in a timely manner.• More effective utilisation of resources, workforce and capacity across the Skin Cancer Managed Clinical Network <p>Potential benefits for Sanofi:</p> <ul style="list-style-type: none">• A clear understanding of the BCC & SCC service and pathways across WoSCAN• Greater understanding of the needs of WoSCAN in supporting best BCC & SCC management.• Improved reputation with WoSCAN.• Optimised patient care within the pathway may lead to appropriate usage of any Sanofi products in line with recognised National and local guidelines.
Contact details	<p><u>Sanofi Aventis</u></p> <p>Fleur Chandler Head of Market Access UK&IE Sanofi Aventis 410 Thames Valley Park Drive, Reading, Berkshire. RG6 1PT. GB-patientaccess@sanofi.com</p> <p><u>NHS</u></p> <p>Heather Wotherspoon MCN & Improvement Manager West of Scotland Cancer Network 1st Floor, St Mungo Building Glasgow Royal Infirmary 84 Castle Street, Glasgow G4 0SF</p> <p>Call: 0141-201-5886 (65886)</p> <p>heather.wotherspoon@ggc.scot.nhs.uk</p>